679 related articles for article (PubMed ID: 16882289)
1. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004).
Sader HS; Streit JM; Fritsche TR; Jones RN
Clin Microbiol Infect; 2006 Sep; 12(9):844-52. PubMed ID: 16882289
[TBL] [Abstract][Full Text] [Related]
2. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
Sader HS; Watters AA; Fritsche TR; Jones RN
BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres.
Sader HS; Farrell DJ; Jones RN
Int J Antimicrob Agents; 2010 Jul; 36(1):28-32. PubMed ID: 20444576
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).
Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):158-62. PubMed ID: 19748426
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of daptomycin against Gram-positive cocci: the first multicentre study in Greece.
Malli E; Spiliopoulou I; Kolonitsiou F; Klapsa D; Giannitsioti E; Pantelidi K; Pratti A; Panopoulou M; Grapsa S; Alepopoulou E; Neonakis I; Frantzidou F; Alexiou-Daniel S; Bakola D; Koutsia-Carouzou C; Malamou-Lada H; Zerva L; Vlahaki E; Kartali-Ktenidou S; Anastassiou ED; Petinaki E
Int J Antimicrob Agents; 2008 Dec; 32(6):525-8. PubMed ID: 18774268
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005).
Pfaller MA; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2007 Apr; 57(4):459-65. PubMed ID: 17240105
[TBL] [Abstract][Full Text] [Related]
8. Update on the in vitro activity of daptomycin tested against 17,193 Gram-positive bacteria isolated from European medical centers (2005-2007).
Sader HS; Moet G; Jones RN
J Chemother; 2009 Nov; 21(5):500-6. PubMed ID: 19933040
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.
Sader HS; Streit JM; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):201-4. PubMed ID: 15541606
[TBL] [Abstract][Full Text] [Related]
10. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
[TBL] [Abstract][Full Text] [Related]
11. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.
Rodloff AC; Leclercq R; Debbia EA; Cantón R; Oppenheim BA; Dowzicky MJ
Clin Microbiol Infect; 2008 Apr; 14(4):307-14. PubMed ID: 18261126
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Dec; 53(4):329-32. PubMed ID: 16263233
[TBL] [Abstract][Full Text] [Related]
14. Assessment of two commercial susceptibility test methods for determination of daptomycin MICs.
Jorgensen JH; Crawford SA
J Clin Microbiol; 2006 Jun; 44(6):2126-9. PubMed ID: 16757608
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008).
Bell JM; Turnidge JD; Sader HS; Jones RN
Pathology; 2010; 42(5):470-3. PubMed ID: 20632825
[TBL] [Abstract][Full Text] [Related]
16. Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006).
Castanheira M; Jones RN; Sader HS
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):235-9. PubMed ID: 18314293
[TBL] [Abstract][Full Text] [Related]
17. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
Int J Antimicrob Agents; 2014 May; 43(5):465-9. PubMed ID: 24636430
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009).
Sader HS; Farrell DJ; Jones RN
J Chemother; 2011 Aug; 23(4):200-6. PubMed ID: 21803696
[TBL] [Abstract][Full Text] [Related]
20. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Huang YT; Liao CH; Teng LJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
